Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans-Reference-Cited by-同舟云学术

Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans

Published:2003-01 Issue:2 Volume:3 Page:97-100
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Werge T,Elbæk Z,Andersen M B,Lundbæk J A,Rasmussen H B

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/6500152.pdf

Reference25 articles.

1. Kane JM, Smith JM . Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473–481.

2. Weinhold P, Wegner JT, Kane JM . Familial occurrence of tardive dyskinesia. J Clin Psychiatry 1981; 42: 165–166.

3. Yassa R, Ananth J . Familial tardive dyskinesia. Am J Psychiatry 1981; 138: 1618–1619.

4. Waddington JL, Youssef HA . The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988; 153:376–381.

5. Rosengarten H, Schweitzer JW, Friedhoff AJ . Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994; 49: 663–667.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroleptic Activity;Drug Discovery and Evaluation: Pharmacological Assays;2016

2. Neuroleptic Activity;Drug Discovery and Evaluation: Pharmacological Assays;2016

3. Neuroleptic Activity;Drug Discovery and Evaluation: Pharmacological Assays;2015

4. A late appearance by the dopamine D-3 receptor;Movement Disorders;2014-07-07

5. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model;Movement Disorders;2014-05-16